Drug intelligence / Profile preview

xB3-002

Development stage: Preclinical
Lead developer: Bioasis Technologies
Modality: RNA Therapeutics → Nucleic Acid Therapeutics, Peptides
Administration: Intravenous

Overview

**xB3-002** is a discovery-stage biOasis Technologies therapeutic program for **glioblastoma**. It is described as an MTfp-miRNA construct that uses the company's xB3 blood-brain-barrier delivery technology, based on a melanotransferrin-derived peptide, to shuttle an miRNA cargo into the central nervous system through receptor-mediated transcytosis. The specific miRNA sequence and its downstream tumor-cell molecular target have not been publicly disclosed.

Other names: MTfp-miRNA

Targets

LRP1 (Prolow-density lipoprotein receptor-related protein 1)

Beyond the preview

Go deeper on xB3-002.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on xB3-002.

Explore the full profile